Back
HIV/AIDS 
HIV/AIDS Topics HIV Prevention Post-exposure Prophylaxis (PEP)
HIV/AIDS Topics HIV Prevention Post-exposure Prophylaxis (PEP)
Raltegravir Shows Long-term Treatment Benefit, Appears Useful for Post-Exposure Prevention
- Details
- Category: Approved HIV Drugs
- Published on Wednesday, 30 May 2012 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) recently approved new product label information for raltegravir (Isentress), adding longer-term data showing that the drug remains effective for more than 3 years. In related news, researchers reported that raltegravir appears to be a good option for post-exposure prophylaxis (PEP) to prevent HIV infection.
Web Design and Development by